Poor
Poorly Aligned
Patient Risk:
Moderate
Summary
Only the prescription-status and listed tablet strengths are supported by the evaluated labeling. Most statements concern coupons, insurance, pricing, or comparative cost and effectiveness, which are not addressed by the prescribing information. The suggestion that a different dose or medication may be equally effective and cheaper is unsupported and could be unsafe if acted on without prescriber guidance.
Category Scores
Accurate Statements
Amitriptyline is a prescription medication.
Supported by the label designation indicating prescription use.
Amitriptyline is available in different dose strengths, including 10 mg, 25 mg, and 50 mg.
Supported by the How Supplied section, which lists 10-mg, 25-mg, and 50-mg tablet strengths.
Unsupported Statements
An amitriptyline coupon is usually a discount offer that lowers the out-of-pocket cost of amitriptyline.
The prescribing information does not address coupons, discounts, or out-of-pocket costs.
Coupons generally apply to the cost paid when insurance benefits are not used.
Insurance and coupon rules are not addressed in the prescribing information.
Depending on the coupon's rules, an amitriptyline coupon may reduce a patient's copay.
Copays and coupon eligibility are not addressed in the prescribing information.
Some coupons cannot be used with certain insurance plans.
Coupon restrictions involving insurance plans are not addressed in the prescribing information.
Some coupons cannot be used when pharmacy insurance coverage is used.
Pharmacy-benefit and coupon restrictions are not addressed in the prescribing information.
Coupon coverage may be limited by formulary status or dosage form.
Formulary status and coupon coverage limitations are not addressed in the prescribing information.
Amitriptyline is available in tablet and other dosage forms.
The evaluated labeling identifies tablet dosage forms but does not establish availability of other FDA-approved dosage forms for the labeled product.
The quantity of amitriptyline tablets dispensed can affect the final savings.
Pricing and the effect of dispensing quantity on savings are not addressed in the prescribing information.
The specific pharmacy and location can affect the final savings for amitriptyline.
Pharmacy-specific and location-specific pricing are not addressed in the prescribing information.
The final savings can depend on whether a generic version of amitriptyline is dispensed.
Generic pricing and savings are not addressed in the prescribing information.
Coupon eligibility may be limited by age, income, or plan type.
Coupon eligibility criteria are not addressed in the prescribing information.
Some coupons exclude certain insurers or government programs.
Coupon exclusions and government-program restrictions are not addressed in the prescribing information.
A pharmacist can provide the lowest-cost generic option for amitriptyline.
Comparative pharmacy pricing and pharmacist selection of the lowest-cost option are not addressed in the prescribing information.
A different dose or an alternative medication may be equally effective and cheaper than the prescribed amitriptyline regimen.
The prescribing information does not establish comparative effectiveness or cost versus alternative drugs or regimens.
Contradictions
Important Omissions
The response does not distinguish clearly between information outside the prescribing information and drug-label-supported information.
Importance:
Moderate
The response does not state that patients should not change the amitriptyline dose or medication based solely on cost considerations without prescriber guidance.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Most unsupported statements concern cost and coupon rules and are unlikely to create direct drug-related risk. However, suggesting that a different dose or alternative medication may be equally effective and cheaper is not established by the prescribing information and could lead to inappropriate treatment changes if acted on without prescriber guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Poorly Aligned
Primary Issue
Most claims are outside the scope of the prescribing information, and the comparative-effectiveness statement about changing dose or medication is unsupported.
Suggested Improvement
Limit label-based claims to supported prescription status and labeled tablet strengths. Clearly identify coupon, insurance, and pricing information as outside the prescribing information, and remove or qualify the suggestion to change dose or medication without prescriber guidance.